Tevogen Bio Signs Letter Of Intent With CD8 Technology To Build Up To A $50M R&D And Manufacturing Facility; No Impact On Shareholder Equity
Tevogen Bio Signs Letter Of Intent With CD8 Technology To Build Up To A $50M R&D And Manufacturing Facility; No Impact On Shareholder Equity
Tevogen Bio與CD8科技簽署意向書，建立高達5000萬美元的研發和製造設施；對股東權益沒有影響
- CD8 Technology Services, LLC ("CD8 Technology") to provide turn-key facility for Tevogen Bio
- Reinforces Tevogen Bio's commitment to preserving shareholder value
-
Expected to further enhance Tevogen Bio's ambitious growth agenda
- CD8科技服務有限責任公司（"CD8 Technology"）爲Tevogen Bio提供一站式設施
- 強化Tevogen Bio對保護股東價值的承諾
- 預計將進一步增強Tevogen Bio雄心勃勃的增長計劃
WARREN, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, took significant steps toward expanding R&D and manufacturing capabilities.
2024年10月29日，新澤西州禾倫（WARREN, N.J.）（環球新聞通訊社）-- 臨床階段的特種免疫療法生物技術公司Tevogen Bio（"Tevogen"或"Tevogen生物控股公司"）（納斯達克:TVGN）正在發展用於治療傳染病和癌症的無需基因修飾的t細胞療法產品，邁出了擴展研發和製造能力的重要一步
The proposed facility is intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.
擬議設施旨在支持Tevogen的臨床前研究和GMP製造功能，由Tevogen的員工負責。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間